|
US6596850B1
(en)
*
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
|
US20010011125A1
(en)
*
|
1997-01-30 |
2001-08-02 |
William D. Huse |
Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
|
|
US6590079B2
(en)
*
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
|
AU768329B2
(en)
*
|
1998-12-04 |
2003-12-11 |
Novartis Ag |
Methods and compositions useful for targeting activated vitronectin receptor alphavbeta3
|
|
US6521593B1
(en)
*
|
1999-02-01 |
2003-02-18 |
Childrens Hospital Los Angeles |
Methods for inhibiting brain tumor growth
|
|
US6531580B1
(en)
*
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
|
EP1227847A2
(en)
*
|
1999-10-06 |
2002-08-07 |
Basf Aktiengesellschaft |
Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
WO2001059142A1
(en)
*
|
2000-02-09 |
2001-08-16 |
Medimmune, Inc. |
Antibody gene therapy with adeno-associated viral vectors
|
|
EP2341075A1
(en)
*
|
2000-03-01 |
2011-07-06 |
MedImmune, LLC |
Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
|
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
EP1372720A4
(en)
*
|
2001-03-02 |
2006-07-26 |
Medimmune Inc |
PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3
|
|
WO2002085405A2
(en)
*
|
2001-04-24 |
2002-10-31 |
Merck Patent Gmbh |
COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
|
|
IL161162A0
(en)
*
|
2001-10-10 |
2004-08-31 |
Pharmacia Italia Spa |
Methods for preventing and treating bone loss with steroid compounds
|
|
US7390885B2
(en)
|
2001-11-26 |
2008-06-24 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
|
US7365167B2
(en)
|
2001-11-26 |
2008-04-29 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
|
AU2003217930A1
(en)
*
|
2002-03-04 |
2003-09-22 |
Medimmune, Llc |
The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
|
|
CA2478317A1
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
|
|
EP1513879B1
(en)
*
|
2002-06-03 |
2018-08-22 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
|
JP2006516635A
(ja)
*
|
2003-01-30 |
2006-07-06 |
メディミューン，インコーポレーテッド |
インテグリンαｖβ３アンタゴニストの使用
|
|
CA2512174A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Christian B. Allan |
Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof
|
|
GB0302699D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Univ Bradford |
Immunoglobulin
|
|
JP4764818B2
(ja)
|
2003-04-11 |
2011-09-07 |
メディミューン，エルエルシー |
組換えｉｌ−９抗体およびその使用
|
|
US7351739B2
(en)
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
|
US8187595B2
(en)
|
2004-05-07 |
2012-05-29 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
|
|
WO2005117936A2
(en)
|
2004-05-07 |
2005-12-15 |
The University Of North Carolina At Chapel Hill |
Method for enhancing or inhibiting insulin-like growth factor-i
|
|
EP1778726A4
(en)
*
|
2004-08-16 |
2009-03-18 |
Medimmune Inc |
INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
|
|
US20060121042A1
(en)
|
2004-10-27 |
2006-06-08 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
EP1819732A2
(en)
|
2004-12-06 |
2007-08-22 |
Kirin Beer Kabushiki Kaisha |
Human monoclonal antibodies to influenza m2 protein and methods of making and using same
|
|
ES2547463T3
(es)
|
2005-06-17 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
Moléculas de unión a ILT3 y usos de las mismas
|
|
EP1893647A2
(en)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
US7777008B2
(en)
|
2006-06-19 |
2010-08-17 |
Tolerx, Inc. |
ILT3 binding molecules and uses therefor
|
|
AU2007272970C1
(en)
|
2006-07-11 |
2013-01-10 |
Roy C. Levitt |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
|
EP3669878A1
(en)
|
2006-08-10 |
2020-06-24 |
Roy C. Levitt |
Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
|
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
|
WO2008144484A1
(en)
*
|
2007-05-16 |
2008-11-27 |
Sinomab Bioscience Limited |
Functional humanization of complementarity determining regions (cdrs)
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US8633139B2
(en)
|
2007-12-21 |
2014-01-21 |
Abbvie Biotherapeutics Inc. |
Methods of screening complex protein libraries to identify altered properties
|
|
WO2010004438A2
(en)
|
2008-06-16 |
2010-01-14 |
Patrys Limited |
Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
|
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
ES2668104T3
(es)
|
2011-12-28 |
2018-05-16 |
Immunoqure Ag |
Procedimiento de aislamiento de anticuerpos humanos
|
|
CN104768975A
(zh)
|
2012-08-31 |
2015-07-08 |
北卡罗来纳大学教堂山分校 |
用于增强或抑制胰岛素-样生长因子1(igf-1)的单克隆抗体
|
|
CN112358548B
(zh)
|
2013-07-03 |
2024-10-25 |
因美诺克股份公司 |
人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法
|
|
EP4353318A3
(en)
|
2017-03-31 |
2024-07-17 |
The Regents of the University of California |
Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
|
|
KR102098462B1
(ko)
*
|
2018-03-14 |
2020-04-08 |
가톨릭대학교 산학협력단 |
αvβ3 인테그린 표적 단일 도메인 항체
|
|
EP4081552A4
(en)
*
|
2020-02-17 |
2024-01-24 |
University of Virginia Patent Foundation |
Car t cells targeting the integrin alphav beta3 exhibit robust anti-tumor responses against gliomas and other solid tumor malignancies
|